Journal article
Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial
Abstract
BACKGROUND: The platelet glycoprotein IIb/IIIa inhibitors, although effective in reducing ischaemic complications of percutaneous coronary intervention, are used in few coronary stent implantation procedures. ESPRIT (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy) is a randomised, placebo-controlled trial to assess whether a novel, double-bolus dose of eptifibatide could improve outcomes of patients undergoing …
Authors
investigators TE
Journal
The Lancet, Vol. 356, No. 9247, pp. 2037–2044
Publisher
Elsevier
Publication Date
12 2000
DOI
10.1016/s0140-6736(00)03400-0
ISSN
0140-6736